Pyrilutamide phase 3 results and maintenance? Research/Science 4/1/2024
Pyrilutamide phase 3 results showed little to no significant hair regrowth, but may be sufficient for maintaining current hair density. The user is unsure due to lack of recent discussions on pyrilutamide.
View this post in the Community →
Similar Community Posts Join
5 / 5 resultscommunity Don’t Get Too Hyped About PP405. We've Seen This Movie Before.
PP405 is a new hair loss treatment showing early promise with a 20% hair density increase, but skepticism exists due to past failures of similar treatments like Pyrilutamide, RU58841, and Bimatoprost. Users debate its potential effectiveness, with some hopeful due to Google's involvement, while others urge caution without more evidence.
community Serious question, is there nothing that can be done if Dutasteride doesn’t help to stop my hair loss?
A 25 year old male who has been using finasteride and dutasteride for two years to treat his hair loss, with no success. Other treatments such as oral minoxidil, topical anti-androgens, RU58841, latanoprost, topical estrogen, CB 03 01, microneedling, keto 2% shampoo, vitamin D, Omega 3, B vitamins and probiotics were discussed.
community People are misunderstanding PP405. 31% response at 8 weeks is better than you think
PP405 shows promise as a hair loss treatment, with 31% experiencing increased hair density in a short trial. It may complement treatments like finasteride and minoxidil, but long-term effectiveness and safety need confirmation.
community The future of hair loss drugs.
Clascoterone 5% and PP405 are being discussed as potential future treatments for hair loss, with clascoterone nearing phase three completion and PP405 possibly taking a cosmetic route to market. Current treatments like minoxidil, finasteride, and RU58841 are mentioned as effective in slowing hair loss, but a complete cure remains elusive.
community I interviewed Kintor: GT20029 Clinical Trial Pictures. As well as KX826.
GT20029 and KX826 are promising hair loss treatments, with GT20029 increasing hair count and KX826 showing significant results. KX826 may be a good alternative for those who can't use finasteride or dutasteride, though results vary.
Related Research
6 / 6 results
research Androgenetic Alopecia: Therapy Update
This comprehensive review analyzes androgenetic alopecia treatments, discussing the mechanisms, costs, efficacy, and safety of FDA-approved drugs like minoxidil and finasteride, as well as newer non-FDA-approved options that have shown effectiveness across various studies.
research ADVANCEMENTS IN TREATMENT STRATEGIES FOR ANDROGENETIC ALOPECIA: NOVEL THERAPIES AND FUTURE PERSPECTIVES
This review identified emerging therapies for androgenetic alopecia, such as low-dose oral minoxidil and stem cell-based treatments, which show promise for improved hair loss management but require standardized protocols and large-scale trials for further validation.
research Focused Review on Metal Nanoparticles in Hair Regeneration and Alopecia: Insights into Mechanisms, Assessment Techniques, Toxicity, Regulatory and Intellectual Property Perspectives
This review explores the potential of metal nanoparticles as innovative treatments for alopecia, highlighting their effectiveness in promoting hair regrowth, enhancing drug delivery, and modulating gene expression while also assessing the related experimental methodologies and regulatory considerations.
research The Hormonal Background of Hair Loss in Non-Scarring Alopecias
This review examines the hormonal causes of hair loss, noting how androgen excess can lead to follicle miniaturization and linking estrogen deficiency and thyroid dysfunction to common alopecia types. It further discusses hormonal treatments such as finasteride, dutasteride, and spironolactone.
research Topical solutions for androgenetic alopecia: evaluating efficacy and safety
This review evaluates various topical treatments for androgenetic alopecia but does not provide new clinical findings, emphasizing the need for selecting therapies with limited systemic side effects.
research Nouvelles thérapeutiques dans la prise en charge de l’alopécie androgénétique
This thesis investigates the underlying mechanisms and treatment options for androgenetic alopecia, highlighting the molecular roles of androgens and genetic predispositions, and evaluates current and emerging therapies, such as PROTACs and Janus Kinase inhibitors, to enhance patient management.